The health sector faces challenges as Novo Nordisk's sales projections dim, Johnson & Johnson's unit faces hefty fines, and ...
Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback